论文部分内容阅读
2015年5月,国家发改委等7部委共同发布《关于印发推进药品价格改革意见的通知》,实现“最高零售限价”向“医保支付标准”的转变。但目前对于药品支付标准价格调整研究欠缺。我国台湾地区从1999年开始进行定期的药价调查以及相应的调整工作,形成目前以创新程度为基础药品分类、总额控费与个体调价相结合的定期药品支付价格调整体系,且成效显著。通过分析台湾地区药品支付价格调整体系,为我们构建药品支付标准价格调整体系提供借鉴。
In May 2015, 7 ministries and commissions including the National Development and Reform Commission jointly released the Notice on Printing and Distributing Opinions on Promoting the Reform of Pharmaceutical Price, realizing the transition from the “highest retail price limit” to the “medical insurance payment standard”. However, there is a lack of research on price adjustment of drug payment standards. China’s Taiwan region from 1999 onwards regular price survey and the corresponding adjustment work to form the current level of innovation based on the classification of medicines, the total amount of control and the individual price adjustment combination of regular drug payment price adjustment system, and achieved remarkable results. By analyzing the drug payment price adjustment system in Taiwan, we provide a reference for us to build a standard system for the price adjustment of pharmaceuticals.